Laboratorios Normon S.A.

28 trials 3 recruiting Commercial sponsor Merged from 2 name variants

Filter these 28 trials by condition, phase, country and more.

Open in Search →

28 Registered trials

3 Recruiting

25 Completed trials

2 Countries active

11 Unique IMPs

100% Results reported

Other

Phase III: 2 Phase II: 1 Other: 25

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

25 of 25 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Actinic keratosis 1 Streptococcal impetigo 1 Staphylococcal impetigo 1 Impetigo 1 Bullous impetigo 1

Top IMPs

ATORVASTATIN CALCIUM, EZETIMIBE 3 ATORVASTATIN, EZETIMIBE 3 VALSARTAN, SACUBITRIL 2 ACICLOVIR 1 APIXABAN 1 EZETIMIBE, ROSUVASTATIN 1 EZETIMIBE, ROSUVASTATIN ZINC 1 HYDROCHLOROTHIAZIDE 1 IMIQUIMOD 1 MUPIROCIN 1 PREGABALIN 1

All trials — page 2

28 total

Bioequivalence clinical trial of two formulations of apixaban Ended

2023-503970-19-00 1 country APIXABAN
Bioequivalence clinical trial of two formulations of sacubitril/valsartan Ended

2022-503083-32-00 1 country VALSARTAN, SACUBITRIL
Bioequivalence clinical trial of two formulations of rosuvastatin/ezetimibe. Ended

2022-501862-24-00 1 country EZETIMIBE, ROSUVASTATIN; EZETIMIBE, ROSUVASTATIN ZINC
Bioequivalence clinical trial of two formulations of Pregabalin 300 mg. Ended

2022-501160-18-00 1 country PREGABALIN

Showing 25–28 of 28 trials

← All sponsors A–Z